PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION

International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification[6]: A61K 31/40	A1	(11) International publication number: WO 99/51224	
		(43) International publication date: 14 October 1999 (14.10 99)	

(21) International application number: PCT/EP99/01918

(22) International filing date: 22 March 1999 (22.03.99)

(30) Data relating to the priority:
198 14 838.0 2 April 1998 (02.04.98) DE

(71) Applicant: ASTA MEDICA AKTIENGESELLSCHAFT [DE/DE]; An der Pikardie 10, D-01277 Dresden (DE).

(72) Inventors: NICKEL, Bernd; Alleestrasse 35, D-64367 Mühltal (DE). SZELENYI, Istvan; Händelstrasse 32, D-90571 Schwaig (DE). SCHMIDT, Jürgen; Am Roggersberg 20, D-88690 Uhldingen-Mühlhofen (DE). EMIG, Peter; Ludwig-Erhard-Strasse 22, D-63486 Bruchköbel (DE). REICHERT, Dietmar; Elsavastrasse 79, D-63863 Eschau (DE) GÜNTHER, Eckhard; Wingertstrasse 176, D-63477 Maintal (DE). BRUNE, Kay; Weiherackerweg 17, D-91080 Marloffstein (DE)

(81) Designated states: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With the International Search Report.
Before expiry of the period provided for amending the claims. Further publication will be made if such amendments are received.




G00002

As printed

(54) Title: INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH ANTITUMORAL ACTIVITY

(54) Bezeichnung: INDOLYL-3-GLYOXYLSÄURE-DERIVATE MIT ANTITUMORWIRKUNG



(1)



162162

(57) Abstract

The invention relates to the use of N-substituted indol-3-glyoxyamides of general formula (1) as antitumoral agents, as well as to pharmaceutical compositions with an antitumoral activity characterised in that they contain at least one of the compounds of general formula (1), possibly in the form of their physiologically acceptable acid addition salts or N oxides. The invention also relates to antitumoral agents containing as active ingredient one or more N-substituted indol-3-glyoxyamides of general formula (1) and their physiologically acceptable acid addition salts, and as far as possible their N-oxides, as well as a pharmaceutically acceptable carrier and/or diluent or additive, in the form of tablets, dragées, capsules, solutions for infusion or ampoules, suppositories, dressings, powder preparations for inhalation, suspensions, creams and ointments.

(57) Zusammenfassung

Die Erfindung betrifft die Verwendung von N-substituierten Indol-3-glyoxylamiden der allgemeinen Formel (1) als Antitumormittel sowie pharmazeutische Zusammensetzung mit Antitumorwirkung, gekennzeichnet durch einen Gehalt an mindestens einer der Verbindungen der allgemeinen Formel (1) ggf. auch in Form der physiologisch verträglichen Säureadditionssalze oder N-Oxide. Ferner umfasst die Erfindung auch Antitumormittel enthaltend als aktiven Wirkstoff ein oder mehrere N-substitierte Indol-3-glyoxylamide gemäss der allgemeinen Formel (1) sowie ggf. deren physiologisch verträglichen Saureadditionssalze und, sofern möglich, N-Oxide und einen pharmazeutisch verwendbaren Trager- und/oder Verdunnungs- bzw. Hilfsstoff in Form von Tabletten, Dragees, Kapseln, Lösungen zur Infusion oder Ampullen, Suppositorien, Pflaster, inhalativ einsetzbaren Pulverzubereitungen, Suspensionen, Cremes und Salben.

ONLY FOR INFORMATION

Codes used to identify the PCT member States on the flyleaves of the brochures in which international applications made under the PCT are published.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaidjan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia-Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	Former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Fasso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Vietnam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrghyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Ivory Coast	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakhstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		